Manuka honey, produced from the nectar of a flowering plant native to Australia and New Zealand, showed significant anti-Pseudomonas aeruginosa activity in an experimental model of lung infection designed to closely replicate the pulmonary environment of patients with cystic fibrosis (CF). The results were reported in the study “Anti-pseudomonad…
News
Armata Pharmaceuticals‘ investigational phage therapy AP-PA01 combined with antibiotics holds promise for treating multidrug-resistant Pseudomonas airway infections, updated data from a case study show. A young woman with cystic fibrosis (CF) was successfully treated for a multidrug-resistant Pseudomonas aeruginosa pneumonia using AP-PA01 and antibiotics. At 100 days…
Vertex Pharmaceuticals selected its VX-445 (elexacaftor) triple regimen to apply for regulatory approvals in the U.S. and Europe over the third and fourth quarters of 2019. The therapeutic regimen is intended for the treatment of cystic fibrosis…
Inhalation of nitric oxide as an add-on therapy may help reduce the burden of serious bacterial lung infections, namely the hard-to-treat Mycobacterium abscessus, in cystic fibrosis (CF) patients, AIT Therapeutics announced. The study with that finding, “Pilot study to test inhaled nitric oxide in cystic fibrosis…
International Biophysics, the maker of AffloVest, announced that it is continuing to support people with cystic fibrosis and efforts to raise awareness about this disease, donating 50 of its airway clearance therapy vests to be distributed across the U.S. AffloVests are being given away, one in each state,…
Treatment with ABBV-2222, an investigational CFTR corrector formerly known as GLPG2222, was well-tolerated and partially corrected the function of the CFTR protein, both alone and in combination with Kalydeco (ivacaftor), in a group of patients with cystic fibrosis (CF), Phase 2 clinical trials show. Trial findings…
AzurRx BioPharma has reached its patient enrollment goal in the ongoing Phase 2 trial testing the effectiveness of MS1819-SD, the company’s investigational therapy for the treatment of patients with exocrine pancreatic insufficiency (EPI) associated with cystic fibrosis (CF). MS1819-SD is a recombinant (artificial) form of an enzyme…
Long-term treatment with Kalydeco (ivacaftor) is well-tolerated and efficient, with improvements in sweat chloride concentration, growth, and pancreas function maintained over 84 weeks in 2-to-5-year-old children with cystic fibrosis (CF), results from the Phase 3 KLIMB extension study show. Trial findings were published in the study, “An…
View this post on Instagram …
A mouse model carrying the most common mutation in the CFTR gene (the gene defective in patients with cystic fibrosis) shows disturbances in genes regulating the sleep cycle known as the circadian clock. The study “Dysregulation of Circadian Rhythm Gene Expression in Cystic Fibrosis Mice” was published in the…
Your CF Community
Visit the Cystic Fibrosis News Today forums to connect with others in the CF community.